2017, Number 1
Clinical results with the diacerein chondromodulator for mild to moderate osteoarthritis of the knee Controlled, randomized, blinded, multicenter clinical trial
PDF size: 189.20 Kb.
ABSTRACTObjective: Although diacerein was introduced in 1994 in other countries, the current literature has not established a defined role for chondroprotectives according to Cochrane. The aim of the study is to demonstrate the effects of diacerein in osteoarthritis patients based on functional assessment with analog pain scale, index Knee Society and Western Ontario and McMaster Universities Arthritis index (WOMAC index). We tested the null hypothesis of no difference between treatment with and without diacerein in terms of pain relief and improved function. Methods: 100 patients with osteoarthritis of the knee were randomly divided into two groups, with group 1 patients with only anti-inflammatory treatment and group 2 patients with inflammatory plus diacerein. They were followed for 6 months. WOMAC index, the modified Knee Society Score and visual analog scale were applied. Results: Both groups showed improvement from the initial assessment on WOMAC index but significant difference at 6 months for the 3 scores. Women showed a significant improvement in only 1 of 6 possible combination of evolution-treatment (WOMAC index), while men showed significant improvement in 5 out of 6 (all measurements except the Knee Society Score). Conclusion: Differences between patients with and without diacerein with respect to pain relief and improved function at 6 months follow up. Women showed lower response to treatment compared to men in the 3 evaluation scales.
National Center for Health Statistics. National hospital discharge surveys, data tapes. Facts about Total Hip and Total Knee Replacement. Data extracted and analyzed by the American Academy of Orthopaedic Surgeons, Department of Research and Scientific Affairs. Rosemont, IL: American Academy of Orthopaedic Surgeons; 1995.
Pelletier JP, Mineau F, Fernandes JC, Duval N, Martel-Pelletier J. Diacerhein and rhein reduce the interleukin 1beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol. 1998; 25 (12): 2417-2424.
Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in oa of the hip. Arthritis Rheum. 2001; 44 (11): 2539-2547.